Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343921 | 1.00 | MAP4K4 (0.66) | MAP4K4HDAC1GPR119SUV39H2EIF2AK4 | |
| SCHEMBL2343918 | 1.00 | MAP4K4 (0.66) | MAP4K4HDAC1GPR119SUV39H2EIF2AK4 | |
| SCHEMBL31703517 | 0.86 | MAP4K4 (0.50) | MAP4K4HDAC1EIF2AK4DPP4NR1H2 | |
| SCHEMBL2338338 | 0.83 | MAP4K4 (0.56) | MAP4K4HDAC1GPR119SUV39H2EIF2AK4 | |
| SCHEMBL2338334 | 0.83 | MAP4K4 (0.56) | MAP4K4HDAC1GPR119SUV39H2EIF2AK4 | |
| SCHEMBL2342450 | 0.83 | MAP4K4 (0.56) | MAP4K4HDAC1GPR119SUV39H2EIF2AK4 | |
| SCHEMBL31327927 | 0.82 | MAP4K4 (0.62) | MAP4K4HDAC1GPR119SUV39H2HDAC2 | |
| SCHEMBL31104931 | 0.82 | MAP4K4 (0.62) | MAP4K4HDAC1GPR119SUV39H2HDAC2 | |
| SCHEMBL31105213 | 0.82 | MAP4K4 (0.62) | MAP4K4HDAC1GPR119SUV39H2HDAC2 | |
| SCHEMBL30426722 | 0.82 | MAP4K4 (0.62) | MAP4K4HDAC1GPR119SUV39H2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20140200224-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-17 | — | — | US | disclosed |
| US-20140200224-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-17 | — | — | US | disclosed |
| EP-2203426-B9 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20110319421-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO., KG (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319421-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO., KG (DE) | 2011-12-29 | — | — | US | disclosed |
| US-20110319421-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO., KG (DE) | 2011-12-29 | — | — | US | disclosed |
| EP-2203426-B1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2203426-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009056600-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885 |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885 |
| US-20140200224-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | MAP4K4 1726/4885HDAC1 3464/4885GPR119 235/4885 |
| US-20110319421-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.